Yomeishu Seizo Co., Ltd. (JP:2540)
:2540
Top Page
Yomeishu Seizo Co., Ltd.
(2540)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥4,091.00
▼(-14.77% Downside)
Action:ReiteratedDate:02/26/26
The score is held up by an exceptionally conservative, debt-free balance sheet, but is reduced by weakening profitability and materially negative free cash flow. Technical indicators also point to near-term downside momentum, and valuation looks demanding given the very high P/E and only modest dividend yield.
Positive Factors
Debt-free balance sheet
Zero debt and a large equity base provide durable financial flexibility, lowering insolvency risk and enabling the company to fund operations, investments or shareholder returns without refinancing pressure. This stability supports long-term strategic options and resilience in downturns.
Negative Factors
Weakened profitability
A meaningful drop in net margin signals reduced earnings quality and less room to absorb shocks. Persistently lower margins constrain retained earnings for reinvestment, reduce return on capital, and may hamper the company's ability to deliver consistent shareholder returns over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero debt and a large equity base provide durable financial flexibility, lowering insolvency risk and enabling the company to fund operations, investments or shareholder returns without refinancing pressure. This stability supports long-term strategic options and resilience in downturns.
Read all positive factors
Yomeishu Seizo Co., Ltd. (2540) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥55.37B
Dividend Yield0.95%
Average Volume (3M)33.22K
Price to Earnings (P/E)99.6
Beta (1Y)0.07
Revenue Growth-0.50%
EPS Growth-18.80%
CountryJP
Employees301
SectorConsumer Defensive
Sector Strength42
IndustryBeverages - Wineries & Distilleries
Share Statistics
EPS (TTM)13.75
Shares Outstanding16,500,000
10 Day Avg. Volume53,310
30 Day Avg. Volume33,223
Financial Highlights & Ratios
PEG Ratio-2.08
Price to Book (P/B)0.88
Price to Sales (P/S)4.07
P/FCF Ratio-15.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Yomeishu Seizo Co., Ltd. Business Overview & Revenue Model
Company Description
Yomeishu Seizo Co., Ltd. produces and sells herbal liqueurs and pharmaceutical products in Japan, Hong Kong, Malaysia, Singapore, and Taiwan. It offers Yomeishu, an herbal liqueur; ginger, ginseng, honey, and medicinal liqueur; fruit and herbs liq...
How the Company Makes Money
Yomeishu Seizo Co., Ltd. generates revenue primarily through the sale of its health-focused beverages, with the Yomeishu tonic being its flagship product. The company markets its products through various retail channels, including supermarkets, ph...
Yomeishu Seizo Co., Ltd. Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
88
Very Positive
Cash Flow
41
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.99B | 10.02B | 10.24B | 10.65B | 10.58B | 10.38B |
| Gross Profit | 5.63B | 5.42B | 5.92B | 6.42B | 6.49B | 6.18B |
| EBITDA | 965.15M | 845.01M | 1.04B | 1.60B | 1.58B | 1.14B |
| Net Income | 784.60M | 679.58M | 952.82M | 1.02B | 949.90M | 807.56M |
Balance Sheet | ||||||
| Total Assets | 52.55B | 53.70B | 54.60B | 49.77B | 48.82B | 48.12B |
| Cash, Cash Equivalents and Short-Term Investments | 5.05B | 5.71B | 8.15B | 8.93B | 5.89B | 9.14B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.92B | 7.64B | 7.95B | 6.98B | 6.64B | 6.56B |
| Stockholders Equity | 45.63B | 46.06B | 46.64B | 42.79B | 42.18B | 41.56B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.67B | -1.82B | 1.46B | 1.31B | 774.60M |
| Operating Cash Flow | 0.00 | 473.12M | 667.52M | 1.75B | 1.81B | 1.41B |
| Investing Cash Flow | 0.00 | -1.19B | 2.31B | -1.45B | -1.40B | -217.20M |
| Financing Cash Flow | 0.00 | -623.03M | -760.15M | -554.77M | -551.81M | -551.50M |
Yomeishu Seizo Co., Ltd. Technical Analysis
Negative
4800.00
Price Trends
4179.40
Negative
4338.40
Negative
4039.55
Negative
Market Momentum
-40.73
Negative
33.70
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2540, the sentiment is Negative. The current price of 4800 is above the 20-day moving average (MA) of 4037.25, above the 50-day MA of 4179.40, and above the 200-day MA of 4039.55, indicating a bearish trend. The MACD of -40.73 indicates Negative momentum. The RSI at 33.70 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2540.
Yomeishu Seizo Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥66.70B | 8.46 | ― | 3.63% | 1.78% | 19.50% | |
64 Neutral | ¥84.14B | 31.69 | ― | 0.65% | 17.33% | 12.37% | |
64 Neutral | ¥12.51B | 5.91 | ― | 3.94% | 11.47% | 29.21% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
52 Neutral | ¥55.37B | 99.65 | ― | 0.95% | -0.50% | -18.80% | |
50 Neutral | ¥88.32B | -2.57 | ― | 1.01% | 6.00% | -139.78% | |
48 Neutral | ¥55.98B | -67.83 | ― | ― | 3.68% | ― |
* Consumer Defensive Sector Average
JP:2540
Yomeishu Seizo Co., Ltd.
4,015.00
1,169.00
41.08%
JP:2585
LIFEDRINK COMPANY INC.
1,608.00
-163.99
-9.25%
JP:2590
DyDo Group Holdings, Inc.
2,742.00
-104.91
-3.69%
JP:2927
AFC-HD AMS Life Science Co., Ltd.
883.00
86.87
10.91%
JP:2931
euglena Co., Ltd.
402.00
-47.00
-10.47%
JP:4526
Riken Vitamin Co., Ltd.
2,925.00
584.28
24.96%
Yomeishu Seizo Co., Ltd. Corporate Events
Yomeishu Seizo Backs Tender Offer in Move Toward Privatization
Feb 25, 2026
Yomeishu Seizo’s board has endorsed a tender offer for its common shares by Reno Co., Ltd., while leaving individual shareholders free to decide whether to tender. The transaction is intended to take the company private and ultimately delist...
Reno Launches Tender Offer for Yomeishu Seizo Shares at ¥4,050
Feb 25, 2026
Reno, Inc. has launched a tender offer to acquire common shares of Yomeishu Seizo Co., Ltd., aiming to purchase up to 9,282,257 shares at 4,050 yen per share. The offer period runs from February 25 to April 8, 2026, with settlement scheduled to be...
Yomeishu Seizo Flags Heavy Extraordinary Losses, Scraps Dividend as It Backs Takeover and Delisting
Feb 24, 2026
Yomeishu Seizo has warned it will book significant extraordinary losses for the fiscal year ending March 31, 2026, driven by about ¥380 million in tender offer-related advisory and legal costs and a ¥2.93 billion impairment on underperfo...
Yomeishu Seizo to Book ¥485 Million Extraordinary Gain From Sale of Unlisted Security
Feb 24, 2026
Yomeishu Seizo Co., Ltd. has resolved at a recent board meeting to sell one unlisted investment security at the request of the investee company. The transaction, scheduled for April 2026, is expected to generate a gain on sale of 485 million yen, ...
Yomeishu to Exit Hisamitsu Stake, Books ¥413 Million Extraordinary Gain
Feb 10, 2026
Yomeishu Seizo Co., Ltd. has resolved to participate in a tender offer launched by Taiyo Kosan Co., Inc. for all 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. that it currently holds as strategic equity, citing the offer’s reasonable ...
Yomeishu Seizo Denies Media Report on Buyout Details, Confirms Privatization Talks Ongoing
Feb 3, 2026
Yomeishu Seizo has clarified that recent Nikkei reports suggesting the company is considering going private, divesting certain businesses including its core Yomeishu business, and potentially involving Tsumura Co. as a buyer are not based on any ...
Yomeishu Seizo Delivers Profit Growth Despite Lower Sales and Confirms Dividend Plan
Jan 29, 2026
For the nine months ended December 31, 2025, Yomeishu Seizo reported non-consolidated net sales of ¥7.33 billion, down 5.2% year on year, but achieved sharp profit recovery, with operating profit up 28.5% to ¥128 million, ordinary profit...
Yomeishu Ends Exclusive Talks With KKR, Shifts Privatization Focus to Largest Shareholder Yuzawa
Jan 4, 2026
Yomeishu Seizo has ended exclusive privatization talks with U.S. private equity fund KKR after concluding that KKR’s tender offer proposals were unlikely to be completed due to the firm stance of its largest shareholder, Yuzawa KK, which sup...
Yomeishu Seizo Denies Imminent Tender Offer Despite Exclusive Talks With KKR
Dec 30, 2025
Yomeishu Seizo has clarified that a recent Bloomberg report suggesting the company is set to be privatized via a tender offer as early as January 2026 is not based on any official company announcement. While the company acknowledged that it has gr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.